Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Proteasome Structure

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

The Proteasome

The Proteasome

Structural Protein Function

Structural Protein Function

Structural proteins are a category of proteins responsible for functions ranging from cell shape and movement to providing support to major structures such as bones, cartilage, hair, and muscles. This group includes proteins such as collagen, actin, myosin, and keratin.
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...

Structural Protein Function

Structural Protein Function

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.

Cell reports·2026

Same author

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2.

bioRxiv : the preprint server for biology·2026

Same author

IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.

Frontiers in immunology·2026

Same author

Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.

Gynecologic oncology·2026

Same author

American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.

CA: a cancer journal for clinicians·2025

Same author

CA turns 75: Looking at the future but never forgetting the roots.

CA: a cancer journal for clinicians·2025

Search research articles

Related Experiment Video

Updated: Feb 8, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

Proteasome inhibitors: structure and function.

Ana T Nunes¹, Christina M Annunziata¹

¹National Cancer Institute, National Institutes of Health, Bethesda, MD.

Seminars in Oncology

|June 25, 2018

Summary

Proteasome inhibitors, like bortezomib, have transformed cancer treatment by targeting the ubiquitin-proteasome pathway crucial for cell survival. These drugs induce apoptosis, offering improved outcomes for patients with hematologic malignancies.

Keywords:

bortezomib multiple myeloma proteasome inhibitors ubiquitin-proteasome pathway

More Related Videos

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

Related Experiment Videos

Last Updated: Feb 8, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Proteasome inhibitors have significantly advanced the treatment of hematologic malignancies since bortezomib's approval in 2003.
Multiple myeloma and mantle cell lymphoma show improved patient outcomes with proteasome inhibitor therapy.
The ubiquitin-proteasome pathway is vital in cancer cells, particularly in multiple myeloma due to high protein turnover.

Purpose of the Study:

To elucidate the structure and function of proteasomes.
To detail the mechanisms of action of proteasome inhibitors.
To understand the therapeutic role of proteasome inhibitors in hematologic malignancies.

Main Methods:

Review of existing literature on proteasome inhibitors and their clinical applications.
Analysis of the ubiquitin-proteasome pathway's role in cancer.
Discussion of the molecular mechanisms underlying proteasome inhibitor efficacy.

Main Results:

Bortezomib, carfilzomib, and ixazomib are approved proteasome inhibitors.
Ongoing research explores new proteasome inhibitors and combination therapies.
Proteasome inhibitors induce apoptosis by disrupting protein degradation.

Conclusions:

Proteasome inhibitors are a cornerstone in treating hematologic malignancies.
Targeting the ubiquitin-proteasome pathway offers a validated therapeutic strategy.
Further research into proteasome inhibitors promises continued advancements in cancer therapy.